Keeping Track: Thumbs Up For Zulresso And Sunosi, Thumbs Down For Zynquista And IV Meloxicam
The latest drug development news and highlights from our US FDA Performance Tracker.
You may also be interested in...
Under deal amendment, Innovent gets Asia rights to Cyramza, Retevmo and pirtobrutinib.
Licensed from PharmaMar for the US market at the start of the year, Jazz Pharmaceuticals is hoping its new small-cell lung cancer therapy, Zepzelca (lurbinectedin), may have potential for other cancer types and in different combinations.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.